Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sabatolimab + NIS793
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
sabatolimab + NIS793 is an experimental combination therapy consisting of two monoclonal antibodies, both developed by Novartis. **Sabatolimab** targets T-cell immunoglobulin domain and mucin domain-3 (TIM-3), an immuno-myeloid regulator expressed on immune and leukemic stem cells, acting as an immunotherapy, primarily studied in myelodysplastic syndromes and acute myeloid leukemia. **NIS793** is a human IgG2 monoclonal antibody antagonist of transforming growth factor beta (TGF-β), investigated for inhibition of TGF-β signaling in tumors to overcome immune evasion and fibrosis, including in advanced solid tumors. This combination is under investigation, including in myelofibrosis, as part of combinatorial immunotherapy regimens and has not been approved for any indication[3][5][7].
- Other names
- sabatolimab + NIS793
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB2 (Transforming growth factor beta 2)TGFB3 (Transforming growth factor beta 3)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on sabatolimab + NIS793.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sabatolimab + NIS793.